RT Journal Article
SR Electronic
T1 Seroclearance of HBsAg in Chronic Hepatitis B Patients after a Tolerance-Breaking Therapy: GM-CSF, followed by Human HBV Vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.18.22273874
DO 10.1101/2022.04.18.22273874
A1 Jimin Zhang
A1 Shuang Geng
A1 Hongyu Jia
A1 Gan Zhao
A1 Weidong Zhao
A1 Jie Yu
A1 Feifei Yang
A1 Haoxiang Zhu
A1 Huan Cai
A1 Lishan Yang
A1 Shuren Zhang
A1 Xian Zhou
A1 Chaofan Li
A1 Fang Yu
A1 Xiang Jin
A1 Shijie Zhang
A1 Xianzheng Wang
A1 Yida Yang
A1 Bin Wang
YR 2022
UL http://medrxiv.org/content/early/2022/04/19/2022.04.18.22273874.abstract
AB Objective Seroclearance of hepatitis B surface antigen (HBsAg) remains a challenge to the functional cure of HBV infection due to an HBV-specific immune tolerance that prevents virus eradication.Methods In this clinical study, chronic hepatitis B patients treated with the standard nucleotide analog (NA) Adefovir Dipivoxil (ADV) or treated with ADV and IFN-α were immunized with granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with Human HBV Vaccine.Results This THRIL-GM-Vac approach (THRee Injections of Low-dose GM-CSF followed by one dose of the HBV Vaccine) has achieved at least a 10-fold reduction of HBsAg level in 10 out of 23 (43.5%) patients tested. Moreover, two out of the ten patients eventually reached seroclearance. Thus THRIL-GM-Vac could break HBV-specific tolerance and boost HBsAg-specific cellular immunity. Consequently, the THRIL-GM-Vac approach could provide effective therapy for patients bearing medium-to-low levels of HBsAg.Conclusion Our findings carry the clinical significance of showing a novel way to break immunotolerance that can tackle the persistent infection manifested as generated by chronic HBV burden in chronic hepatitis B (CHB) patients.What is already known about the subject?Chronic hepatitis B virus (CHB) patients can be controlled with antiviral therapies while rarely cured or functionally cured. In addition to the standard anti-viral treatment, immunotherapeutic approaches may break the HBV established immunotolerance and, in turn, mount effective activation or reactivation of host anti-HBV immunity and can be achieved in HBV-related animal models. However, achieving such a functional cure in CHB patients has been challenging.What are the new findings?We demonstrated in this study that some levels of HBsAg seroclearance in CHB patients were treated with a 3-day treatment of GM-CSF followed by one HBV vaccine for six treatments within one year in addition to the standard of anti-viral treatment.Notably, dynamics of HBsAg declined in responders were correlated with dynamics of HBsAg-specific Treg cells and reciprocally associated with the dynamical changes of HBsAg-specific IFN-γ +CD4+ (Th1) and IFN-γ +CD8+(Tc1) T cells over the course.How might it impact on clinical practice in the foreseeable future?It demonstrates in CHB patients that breaking Treg-immunotolerance can significantly be correlated with reducing the level of HBsAg in the ‘responders’ by immunotherapy.Such correlation can be used to predict outcomes of the efficacy of an immunotherapeutic treatment prior to completing its treatments.The evidence of HBsAg seroclearance in CHB patients by the presented immunotherapeutic approach will also shed light on improving such approach or similar strategies and further benefit those unmet medical needs.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR-TRC-13003254Funding Statementthe National Major Science and Technology Research Projects for the Control and Prevention of Major Infectious Diseases in China (2017ZX10202202, 2013ZX10002001 and 2013ZX10002001003) and National Natural Science Foundation of China (81871640, 82172255).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Research Ethics Committee of Huashan hospital, Fudan University. All the study participants were enrolled in Huashan Hospital, Fudan University, and provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors